Sichuan Hebang Biotechnology Corporation Limited

SHSE:603077 Stock Report

Market Cap: CN¥17.7b

Sichuan Hebang Biotechnology Past Earnings Performance

Past criteria checks 2/6

Sichuan Hebang Biotechnology has been growing earnings at an average annual rate of 18.7%, while the Chemicals industry saw earnings growing at 4.9% annually. Revenues have been growing at an average rate of 12.7% per year. Sichuan Hebang Biotechnology's return on equity is 2.4%, and it has net margins of 5.3%.

Key information

18.7%

Earnings growth rate

18.4%

EPS growth rate

Chemicals Industry Growth12.1%
Revenue growth rate12.7%
Return on equity2.4%
Net Margin5.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Earnings Not Telling The Story For Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077)

Dec 18
Earnings Not Telling The Story For Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077)

Is Sichuan Hebang Biotechnology (SHSE:603077) A Risky Investment?

Nov 19
Is Sichuan Hebang Biotechnology (SHSE:603077) A Risky Investment?

Returns On Capital At Sichuan Hebang Biotechnology (SHSE:603077) Have Stalled

Sep 25
Returns On Capital At Sichuan Hebang Biotechnology (SHSE:603077) Have Stalled

Sichuan Hebang Biotechnology Corporation Limited's (SHSE:603077) Shares Not Telling The Full Story

Aug 16
Sichuan Hebang Biotechnology Corporation Limited's (SHSE:603077) Shares Not Telling The Full Story

Return Trends At Sichuan Hebang Biotechnology (SHSE:603077) Aren't Appealing

Jun 04
Return Trends At Sichuan Hebang Biotechnology (SHSE:603077) Aren't Appealing

Investors Holding Back On Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077)

May 13
Investors Holding Back On Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077)

Is Sichuan Hebang Biotechnology (SHSE:603077) A Risky Investment?

Mar 07
Is Sichuan Hebang Biotechnology (SHSE:603077) A Risky Investment?

Here's Why I Think Sichuan Hebang Biotechnology (SHSE:603077) Is An Interesting Stock

Apr 21
Here's Why I Think Sichuan Hebang Biotechnology (SHSE:603077) Is An Interesting Stock

Revenue & Expenses Breakdown

How Sichuan Hebang Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:603077 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 249,20348650841
30 Jun 249,58285949944
31 Mar 248,42991647947
31 Dec 238,8241,28347147
30 Sep 238,9801,39853472
30 Jun 239,6511,78966969
31 Mar 2312,3473,16179669
31 Dec 2213,0393,80788368
30 Sep 2213,3534,43870134
30 Jun 2213,5174,74161234
31 Mar 2211,4093,81545433
31 Dec 219,9873,01834133
30 Sep 218,4942,24823433
30 Jun 216,76890820336
31 Mar 215,90231926737
31 Dec 205,2614131040
30 Sep 205,115-14745741
30 Jun 205,35126452040
31 Mar 205,56537251040
31 Dec 195,96951749838
30 Sep 196,20038058638
30 Jun 196,15438756334
31 Mar 196,28542657033
31 Dec 186,00936354831
30 Sep 185,99062251737
30 Jun 185,62553545350
31 Mar 184,96139545842
31 Dec 174,73851845935
30 Sep 174,40047743819
30 Jun 174,0414514360
31 Mar 173,7224364190
31 Dec 163,4633183960
30 Sep 163,2062603510
30 Jun 162,9542263280
31 Mar 163,0432553010
31 Dec 152,8632402460
30 Sep 152,7571442390
30 Jun 152,6281352060
31 Mar 152,2826791730
31 Dec 142,1866721790
30 Sep 141,9797151900
30 Jun 141,8716961660
31 Mar 141,660541600
31 Dec 131,603641500

Quality Earnings: 603077 has high quality earnings.

Growing Profit Margin: 603077's current net profit margins (5.3%) are lower than last year (15.6%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 603077's earnings have grown by 18.7% per year over the past 5 years.

Accelerating Growth: 603077's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 603077 had negative earnings growth (-65.3%) over the past year, making it difficult to compare to the Chemicals industry average (-4.7%).


Return on Equity

High ROE: 603077's Return on Equity (2.4%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 18:57
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sichuan Hebang Biotechnology Corporation Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wei LiuHaitong International Research Limited
Turong MaiShenwan Hongyuan Securities